PhD, MSc, BPharm, FHEA
Reader in Forensic Intelligent Data Analytics, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University
Sulaf Assi is a reader in forensic intelligent data analysis at the School of Pharmacy and Biomolecular Sciences in Liverpool John Moores University. She has a Bachelor in Pharmacy and Masters in Pharmaceutical Analysis from Beirut Arab University in Lebanon and a PhD in Pharmaceutical Analysis from the School of Pharmacy in London. Her research interests spread across multidisciplinary and interdisciplinary areas related to medication safety; patient safety; counterfeit medicines, drugs and lifestyle products; spectroscopy; mixed-method research, artificial intelligence and machine learning.
Senior Fellow, Biopharmaceutics, Medicines Product Development, GSK Research & Development, Ware, United Kingdom
James obtained a BSc in Applied Chemistry at Nottingham Trent University, an MSc in Pharmaceutical Technology at Kings College London, and his PhD (part time) from Goethe University Frankfurt am Main.
After working in ophthalmic drug delivery for Smith & Nephew for a few years after his first degree, James moved to GSK in 1993. There, he has worked in various roles, specialising in oral formulation and biopharmaceutics. He has extensive experience in small molecule developability, predictive tools for oral drug absorption, and formulation strategies for low solubility drugs. In his current role, James advises project teams at all stages development on the gastro-intestinal tract behaviour and absorption of oral drugs. He has worked with a range of industry-academic partnerships in biopharmaceutics and related topics and has widely published his work. He is best known for his work on in-vitro tools for the prediction of oral absorption, and on the developability classification system (DCS).
Reader in Molecular Spectroscopy, King's College London
Dr Chan is a Reader in Pharmaceutical Molecular Spectroscopy at King’s College London. He is the programme director of the Pharmaceutical Analysis, Technology and Biopharmaceuticals MSc course and the Education Lead for the School in the Institute of Pharmaceutical Science. He is a member of the Royal Society of Chemistry, the Honorary Event Secretary of the Joint Pharmaceutical and Analysis Group and a member of the Editorial Board for the journal Scientific Reports. Dr Chan has over 90 scientific publications primarily in the development of novel applications of Fourier Transform Infrared (FTIR) spectroscopy for testing pharmaceutical and biological systems including living cells. His research has been supported by the Royal Society, Royal Society of Chemistry, the British Council, EPSRC, BBSRC, MRC and the Diamond Light Source. He currently has an h-index of 37 according to the Web Of Knowledge.
Senior Lecturer in Pharmaceutical Sciences, De Montfort University
Ana Sara Cordeiro is a Senior Lecturer in Pharmaceutical Sciences at the School of Pharmacy at De Montfort University (Leicester, UK). Following a PharmD from the University of Porto (Portugal) and a PhD in Drug Research and Development from the University of Santiago de Compostela (Spain), she worked as a Postdoctoral Research Fellow at Queen's University Belfast (Belfast, UK). Throughout these years, Sara has developed a background in pharmaceutical formulation, drug delivery, nanomedicine, vaccine delivery and microneedles for transdermal drug delivery and diagnostics.
Currently, she is establishing her independent research group (3Ds – Drug Delivery and Diagnostics) with a focus on improving and facilitating patients' lives through the development of drug and vaccine delivery systems that are easy to manufacture and scale-up, highly efficient and administered through non-invasive routes. Sara is also the current Editor-in-Chief of the Controlled Release Society (CRS) Newsletter, and e-media lead for the CRS Women in Science group.
APS Chair
Chair in Pharmaceutical Technology, School of Pharmacy, Queen's University Belfast
Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology at Queen’s University Belfast and is Director of QUB’s interdisciplinary research programme Materials and Advanced Technologies for Healthcare (MATCH). His personal research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and intradermal drug delivery, with a strong emphasis on improving patient outcomes. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with several major pharma partners.
He has obtained substantial UK Research Council, charity and industrial funding and authored over 300 peer-reviewed publications (H-index = 58), including 6 patent applications, 6 textbooks, 23 book chapters and approximately 250 full papers. He has been an invited speaker at numerous national and international conferences. Professor Donnelly is Europe/Africa Editor of Drug Delivery & Translational Research and the Controlled Release Society’s Communications Chair. He has won the Academy of Pharmaceutical Science’s Innovative Science Award (2020), Evonik’s Resomer Award (2018), the Controlled Release Society’s Young Investigator Award (2016), BBSRC Innovator of the Year and the American Association of Pharmaceutical Scientists Pharmaceutical Research Meritorious Manuscript Award (2013), the GSK Emerging Scientist Award (2012) and the Royal Pharmaceutical Society’s Science Award (2011).
PharmSci 2024 Scientific Programme Lead
Professor of Pharmaceutical Technology at the Goethe University in Frankfurt (retired)
Jennifer Dressman served as Assistant and as a tenured Associate Professor at the University of Michigan from 1983 to 1994, and then as Professor of Pharmaceutical Technology at the Goethe University until her retirement in 2021.
Prof. Dressman’s research interests focus principally on predicting the in vivo performance of drugs and dosage forms after oral administration. She is best known for pioneering the use of Biorelevant dissolution testing, publishing Biowaiver Monographs and her contributions to combining dissolution testing with physiologically based pharmacokinetic modelling to achieve quantitative predictions of oral drug absorption.
In recognition of her research excellence, she has been made a Fellow of the AAPS, the CRS, APSTJ and the FIP. In 2008 she was awarded the Distinguished Scientist Award of the FIP and in 2017 was named the International Woman Pharmaceutical Scientist of the Year by the APSTJ. In 2022 a special issue of the Journal of Pharmaceutical Sciences was dedicated to her contributions to the Pharmaceutical Sciences.
Senior Lecturer, Head, The Natural Products Metabolomics Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
Dr Edrada-Ebel currently heads the Natural Products Metabolomics Group (NPMG) at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) and is currently author of more than 150 publications and two patents on marine natural products. She is recently on the top 20 most cited authors for the ACS Journal of Natural Products (ranked 18th https://exaly.com/rankings/author/journal-1/12955/). She is on the advisory board of the European Marine Natural Products Conferences and a committee member of the Society of Chemical Industry (Scotland Group). Her expertise comprises both natural products isolation and structure elucidation with modern spectroscopic techniques. Her current research is based on the application of metabolomics on natural products research to identify and biotechnologically optimize the production of bioactive secondary metabolites in marine-derived microorganisms. She established the Natural Products Metabolomic group in SIPBS in 2011 and has always led a multidisciplinary research group in Natural Products Research. She is amongst the pioneer on creating innovated applications of metabolomics research for the systematic discovery and production of biologically active natural products for novel drugs in microbial endophytes and symbionts. She has also led successful knowledge-exchange projects with Scottish SMEs for further major funding and yielded to date a total funding of £600K from the Knowledge Exchange Hub and ERDF-ENCOMPASS to collaborate with Scottish SMEs. She was also nominated for an Interface Excellence Award for Sustained Partnership. She is also on the advisory board of the European Marine Natural Products Conferences and was the Secretary for Society of Chemical Industry (Scotland Group) for the past 5 years (2017-2022).
Reader in Polymer Therapeutics, School of Dentistry, Cardiff University
Elaine graduated from the University of Manchester with a Master of Pharmacy degree in 2003, before completing a PhD with Prof Ruth Duncan at Cardiff University’s Welsh School of Pharmacy in 2008, in which she developed a bioresponsive polymer-phospholipase conjugate for the treatment of breast cancer. This research initiated Elaine’s long-standing interest in using natural biodegradable polymers as novel carriers for bioactive agents. Having demonstrated the feasibility of bioresponsive polymer therapeutics in cancer, Elaine joined Cardiff University’s School of Dentistry, where her interests focused on exploring new clinical applications, including chronic wound healing, infection and spinal cord injury. Her ongoing research aims to optimise drug release by attachment of biodegradable polysaccharides to protein and peptide drugs, in order to direct them to sites of inflammation, thereby minimising toxicity, overcoming resistance and increasing bioavailability.
PhD, Professor in Molecular Genetics, Deputy Head of Genetics and Genomic Medicines Programme, UCL Great Ormond Street Institute of Child Health
Stephen Hart obtained his PhD in Microbiology from the University of Cape Town in 1991 then undertook a postdoc at St. Mary’s Biochemistry and Molecular Genetics Department before joining the UCL Great Ormond Street Institute of Child Health (ICH) as a postdoc then Lecturer. He was promoted to professor in 2012 and is currently Deputy Head of the Genetics and Genomic Medicines Department at ICH. He has worked in the field of genetic therapies for more than 20 years with a particular focus on non-viral therapies and has more than 100 publications to his name. His current research activities include the development of RNA and gene editing therapies, for the treatment of cystic fibrosis, primary ciliary dyskinesias and neuroblastoma. His group have developed novel synthetic nanoparticles for the delivery of nucleic acid therapeutics including siRNA, messenger RNA and CRISPR/Cas9 formulations. He is the lead investigator on a Strategic Research Centre grant funded by the Cystic Fibrosis Trust and Cystic Fibrosis Foundation, developing CRISPR gene editing therapies for cystic fibrosis. In 2017 he was elected to the board of directors of the American Society of Gene and Cell Therapy, serving until 2021. He is a Senior Editor for the journal Annals of Human Genetics, a member of the editorial board for the journals Gene Therapy and Genes. He is the named inventor on nine patents concerning nanoparticle delivery formulations and was the scientific founder of Nanogenics Ltd, a UCL spin-out company, commercialising nanoparticle delivery formulations for genetic therapies.
Research Group 'Pharmacognosy and Phytotherapy'
UCL School of Pharmacy, University College London
Michael Heinrich is a Professor of Ethnopharmacology and Medicinal Plant Research (Pharmacognosy) and was until 2018 the head of the research cluster / Centre ‘Biodiversity and Medicines’ at the UCL School of Pharmacy. He currently serves as the joint chair of UCL’s Research Ethics Committee (with Dr L. Ang, Institute of Education).
The group's research is based on a transdisciplinary perspective integrating approaches from the biomedical and social sciences with an overall aim of tackling the fast changing global health needs. Key areas of interest include the prevention and early stage management of diabetes/metabolic syndrome and cancer chemoprevention based on the use of traditional medicines as well as value chains of (herbal) medicinal products. The research integrates methodological approaches from ethnopharmacology, natural product research, public health research, and anthropology.
Currently, he is one of the two Vice-Presidents of the GA (Society for Medicinal Plant and Natural Product Research), one of the largest societies in the field.
He is Specialty Editor in Chief of Frontiers in Pharmacology (Ethnopharmacology) as well as an associate editor of the Journal of Pharmacy and Pharmacology, among a wide range of other roles.
Most recent publications:
Professor of Chemistry, Marine Biodiscovery Centre, University of Aberdeen
Marcel Jaspars is Professor of Organic Chemistry at the University of Aberdeen where he leads the Marine Biodiscovery Centre which focuses on marine resources for novel pharmaceuticals, and to investigate fundamental questions in marine chemical ecology and biosynthesis. Marcel founded the interdisciplinary Marine Biodiscovery Centre at the University of Aberdeen in 2010, a £2.5 M investment to focus on marine resources for novel pharmaceuticals, and to investigate fundamental questions in chemical ecology and biosynthesis. The Centre contains facilities for chemistry, chromatography, spectroscopy, molecular genetics and microbiology. Marcel has been active at national and international levels to develop the science, its applications/industrial uptake and associated policy involved in marine biodiscovery and biotechnology. He provides scientific advice to the UK, EU and UN for global policy processes on ocean conservation and digital sequence information.
Consultant Hepatobiliary Surgeon and Honorary Associate Professor of Surgery, NIHR NWC Research Lead for Surgery, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool
Robert is a Consultant Hepatobiliary Surgeon and NIHR Researcher from the University of Liverpool. His main research interests are in advanced and metastatic colorectal cancer and the metastatic immune microenvironment. He is the Chief Investigator for BNT-122, the UK’s first personalised mRNA cancer vaccine study looking at adjuvant vaccine treatment in resected colorectal cancer.
Reader in Pharmaceutical Product Engineering at the University of Strathclyde and Associate Director at CMAC
Daniel Markl is a Reader in pharmaceutical product engineering at the University of Strathclyde and Associate Director at the Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC). His research aims to develop cyber-physical systems and associated, innovative methods for drug product development and manufacturing that accelerate the pace at which new medicines are developed and delivered across important therapeutic areas. This includes the coupling of advanced measurement techniques with digital process and product design tools to resolve the relationship between material attributes, manufacturing conditions and the performance and stability of solid oral dosage forms.
Head of Global Biopharmaceutics, Drug Product Design, Pfizer
Dr Mark McAllister is a Senior Director and Head of Global Biopharmaceutics, part of the Drug Product Design group at Pfizer in Sandwich, Kent. He is a Pharmacy graduate from Queen’s University Belfast and has a pharmaceutics PhD from Aston University. Mark has 30 years industrial development experience and has specialised in oral delivery systems and biopharmaceutics. He is a former chair of the Academy of Pharmaceutical Sciences and is currently a visiting senior lecturer at King’s College London. Mark co-led the IMI ‘OrBiTo’ biopharmaceutics project, an academic/industrial collaboration, focused on the development of the next generation of models to predict oral absorption and he currently participates in a number of pre-competitive research programmes including COLOTAN, AGePOP and InPharma Marie Skłodowska-Curie innovative training networks. Mark is a Fellow of the Royal Pharmaceutical Society and the Academy of Pharmaceutical Sciences.
PhD
Senior Scientific Advisor and Deputy Head of Translational Science in DMPK, Certara UK Ltd., Simcyp Division
Sibylle Neuhoff, PhD, Certara UK ltd (Simcyp division) works in the translational science team as Senior Scientific Advisor in the field of PBPK/PD modelling, oral drug absorption, transport and transporter, metabolism, and toxicity. After qualifying as chemist (Frankfurt am Main, Germany), she received her PhD from the department of pharmacy at the Uppsala University (Sweden).
Sibylle is supervising a team of scientists at Simcyp who extrapolate in vitro data to predict in vivo pharmacokinetics in humans and animals. She is helping to develop and implement models within the Simcyp Simulator, which link the processes of drug discovery and development using simulations in virtual patient populations. She is helping to develop and implement models within the SIVA tool kit for the transport module, which allows modelling of in vitro transport assay data to obtain for instance transporter kinetic data. She is involved in consultancy projects related to application of the Simcyp Simulator within the pharmaceutical industry.
Current research interests include pharmacogenomics of drug-metabolizing enzymes and transporters related to drug disposition and pharmacodynamics, ligand interactions with human metabolising enzymes and transporters, endogenous biomarker, and novel approaches to simulate and/or predict metabolic clearance, metabolic drug-drug interactions, and transporter-related interactions in healthy subjects and patient populations.
Sibylle has taught at more than 50 PBPK workshops on the Simcyp Simulator and SIVA (MIDD, Transporter, FIH, DDI, and Best Practise) and published numerous peer-reviewed journal articles (ORCID 0000-0001-8809-1960). She has given regularly invited talks at national and international meetings and conferences.
Head of Institute and Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
I am a Professor in Drug Delivery at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. I earned my PhD from the University of London in 1998, focusing on liposomes for DNA vaccines and drug delivery. I then worked at Lipoxen Technologies Ltd for two years, developing their liposome drug delivery platform. In 2000, I joined Aston University and became a Professor in Drug Delivery in 2007. I moved to the University of Strathclyde in 2016 as part of the Global Talent Appointment Programme. My multi-disciplinary research focuses on developing drug delivery systems for drugs and vaccines, providing practical healthcare solutions.
Senior Lecturer in Drug Delivery, Head of Chemistry and Drug Delivery Group, Medway School of Pharmacy, University of Kent
Dr Vivek Trivedi is a pharmacist by training who has several years of experience in both the industry and academia. He worked in Dr Reddy’s labs and Phoqus Pharmaceutical Ltd before starting his academic career as a lecturer in formulation science at the University of Greenwich, where he stayed until April 2019. He then moved to the University of Kent where is currently employed as a Senior Lecturer in Drug Delivery and Head of Chemistry and Drug Delivery group at the Medway School of Pharmacy. Dr Trivedi's research is centred around two areas: solubility improvement of BCS II drugs and oral delivery of biomolecules. His interests strongly revolve around the use of green processing methods, such as supercritical carbon dioxide to develop suitable strategies for drug delivery. His research interest around the application of scCO2 centres around the manipulation of the physical properties of drugs and excipients to prepare cyclodextrin-drug complexes and solid dispersion, as well as for loading APIs in organic and inorganic excipients. He is interested in developing formulations to allow nose-to-brain drug delivery of small and large molecules, noninvasively. He has attracted funding from various industrial sources as well as the European Union, Royal Society, and Royal Society of Chemistry to conduct research in these areas.
Professor, University of Huddersfield
Laura is Professor of Pharmaceutical Analysis within the School of Applied Sciences at the University of Huddersfield. Laura is heavily involved in the Royal Society of Chemistry, current treasurer of the local section, a Benevolent Volunteer Visitor, a former member of Council and a current member of the JPAG committee. Laura is also a Fellow of the Higher Education Academy and a STEM ambassador.
Laura has an active research group investigating phenomena at the interface of chemistry and pharmaceutics, developing analytical techniques, characterising chemical interactions and enhancing formulations, all funded through external sources. Her work in the area of public engagement includes public lectures and media presentations and she has appeared on numerous radio programmes, as well as BBC1, BBC2, BBC3, Channel 4 and Channel 5.
Professor of Stem Cell Biology and Regenerative Medicine, University of Reading, School of Pharmacy
Darius Widera is a Professor of Stem Cell Biology and Regenerative Medicine and Research Division Lead at the University of Reading. His lab is mainly interested in adult stem cells and their secretome, inflammatory signalling cascades in health and disease, and novel methods for clinical-grade 3D cultivation of human stem cells. His research is focused on the regenerative potential of mesenchymal stromal cells, neural crest-derived stem cells, and pluripotent stem cells in different disorders and conditions. Lastly, his research aims to tackle disorders and conditions with an inflammatory component, such as osteoporosis, lung, brain, and breast cancer.
He graduated in Biochemistry (Witten/Herdecke University, Germany) and received his PhD in Neurobiochemistry from Witten/Herdecke University, Germany, in 2007. From 2013 to 2015, he served as an Adjunct Professor at the Department of Cell Biology, University of Bielefeld (Germany). In February 2015, he was appointed as a Lecturer in Stem Cell Biology and Regenerative Medicine at the University of Reading, promoted to Associate Professor in 2019, and to full Professor in 2023. Since 2022, Professor Widera has also been the Research Division Lead for the Reading School of Pharmacy at the UoR.
He has published over 90 research manuscripts (h-index of >32, i-10 index of >63) and has presented his research outcomes as invited talks at numerous international conferences in the UK, Germany, USA, Italy, Ireland, Finland, San Marino, Russia, Malaysia, Singapore, Brazil, and China. To date, he has supervised 11 PhD and 26 Master's students to completion. In addition to his academic duties, he has acted as a consultant for UPM Biomedicals and is currently a Scientific Advisory Board Member for Argon Medical Ltd, Germany.
Professor Widera is also actively engaging in science communication, and he has consulted national and international media, including The Times, BBC, Daily Mail, AFP, Nature, and ITN.
Copyright © 2024 APSPharmSci - All Rights Reserved.
Powered by GoDaddy